Benign Conditions

Benign Prostatic Hyperplasia

Bladder Cancer

Female Urology

Genitourinary Cancers

Genomic Testing

Hormone Therapy

Kidney Cancer

Challenging Anatomy

Innovative Techniques

Laser Lithotripsy

PCNL Tech & Devices

Ureteroscopy Tech & Devices

Kidney Stones

Men's Health

Next-Generation Imaging

Voiding Dysfunction

OAB and Incontinence

Pediatrics

Controveries in Urologic Cancer

Drug Therapy

Prostate Cancer

Sexual Dysfunction

UTUC

Cosmetic Surgery

Urologic Surgery

Business

Practice Management

Malpractice Consult

Health Law & Policy

Media

Case-Based Peer Perspectives

Investigator Perspectives 

Medical World News

Podcasts

Urology Medical Perspectives

UTv Videos

Peer Exchange

News Network

Virtual Tumor Board

Insights

Medcast

Peers & Perspectives

Conferences

Conference Listing

Conference Previews 

Conference Recaps

Publications

Urology Times Journal

Editorial Advisory Board

Urologists in Cancer Care

Supplements and Featured Publications

CME/CE

Resources

Begin Your Journey: Tackling Burnout

Live Events

Interactive Tools

Job Board

Partners

Subscribe

Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do not sell my Personnal Information

Urology Times | News & Insights for Urologists & Health Professionals

Facebook

LinkedIn

Spotlight

Peers and Perspectives

Clinical

1rem

View

Exploring Treatments for Metastatic Castration-Sensitive Prostate Cancer

Overcoming Unmet Needs in Treating mCSPC: ADT Monotherapy vs Multimodal Approaches

Video content above is prompted by the following:

What are some of the most critical challenges and unmet needs in the treatment and management of mCSPC?

Videos

Panelists discuss how recent advancements in diagnostic strategies and emerging combination therapies are shaping the management of metastatic castration-sensitive prostate cancer to better address patient needs and improve outcomes.

Panelists discuss how the prevalence of metastatic castration-sensitive prostate cancer (mCSPC) has been increasing, potentially influenced by changes in prostate-specific antigen screening recommendations and rising diagnoses of metastatic hormone-sensitive prostate cancer.

Emerging Trends and Rising Prevalence of  mCSPC

Panelists discuss how metastatic castration-sensitive prostate cancer (mCSPC) is defined by its sensitivity to androgen deprivation therapy, while metastatic hormone-sensitive prostate cancer (mHSPC) emphasizes the cancer’s responsiveness to hormone treatment, highlighting the nuanced differences in patient management strategies.

Defining mCSPC: Diagnostic Criteria, Imaging Approaches, and Patient Identification

Panelists discuss how some of the most critical challenges and unmet needs in the treatment and management of metastatic castration-sensitive prostate cancer (mCSPC) include the effectiveness of monotherapy, the need for better risk stratification, and the integration of novel therapies to improve patient outcomes.

Panelists discuss how management options for nonmetastatic castration-sensitive prostate cancer (nmCSPC) include active surveillance, radiotherapy, and systemic therapy, with recommendations influenced by factors such as tumor volume, prostate-specific antigen (PSA) doubling time, and patient life expectancy, particularly for those with high-volume symptomatic disease.

Managing Biochemical Recurrence in Prostate Cancer: Risk Stratification and Treatment Decisions

Panelists discuss how recent data from the EMBARK study indicates that in patients with nonmetastatic castration-sensitive prostate cancer (nmCSPC) at high risk for biochemical recurrence (BCR), enzalutamide combined with gonadotropin-releasing hormone (GnRH) significantly improves metastasis-free survival compared with monotherapy options, with no new safety signals reported.

Innovative Treatment Strategies in High-Risk Biochemical Recurrence: Insights From the EMBARK Trial

Panelists discuss how guideline-recommended treatment options for metastatic castration-sensitive prostate cancer (mCSPC) include various combinations of androgen deprivation therapy, docetaxel, and novel hormonal agents, tailored to the patient’s disease characteristics and overall health.

Navigating Treatment Options in mCSPC: Choosing the Right Doublet or Triplet Therapy

Panelists discuss how managing cognitive and sexual health in prostate cancer patients undergoing hormonal therapy is crucial, emphasizing the need for proactive communication and tailored interventions to enhance overall quality of life.

Managing Cognitive and Sexual Health in Prostate Cancer Patients on Hormonal Therapy 

Metastatic castration-sensitive prostate cancer (mCSPC) presents several critical challenges and unmet needs in its treatment and management. Despite advancements, there remains a need for more effective therapeutic strategies to improve patient outcomes. The complexity of mCSPC requires personalized treatment approaches, considering factors such as disease burden, patient comorbidities, and genetic profiles. Additionally, there is a need for better biomarkers to guide treatment decisions and predict responses. Addressing these challenges is crucial for optimizing care and improving survival rates for patients with mCSPC.

Overcoming Unmet Needs in Treating mCSPC: ADT Monotherapy vs Multimodal Approaches

Key Takeaways

EP: 1.Emerging Trends and Rising Prevalence of mCSPC

EP: 2.Defining mCSPC: Diagnostic Criteria, Imaging Approaches, and Patient Identification

EP: 3.Overcoming Unmet Needs in Treating mCSPC: ADT Monotherapy vs Multimodal Approaches

EP: 4.Managing Biochemical Recurrence in Prostate Cancer: Risk Stratification and Treatment Decisions

EP: 5.Innovative Treatment Strategies in High-Risk Biochemical Recurrence: Insights From the EMBARK Trial

EP: 6.Navigating Treatment Options in mCSPC: Choosing the Right Doublet or Triplet Therapy

EP: 7.Managing Cognitive and Sexual Health in Prostate Cancer Patients on Hormonal Therapy